EUVIMEDOpdag EUVIMED
Multizentrische Studie

A change in the timing for starting systemic therapies for hepatocellular carcinoma : the comparison of sorafenib and lenvatinib as the first-line treatment

T Hatanaka, S Kakizaki, T Nagashima, T Ueno, M Namikawa, H Tojima, D Takizawa, A Naganuma, H Arai, K Sato, N Harimoto, K Shirabe and 1 more

Acta Gastro Enterologica Belgica · 2021

DOI: 10.51821/84.1.109 ↗

At a glance

Multizentrische Studie in Acta Gastro Enterologica Belgica, 2021. Written by T Hatanaka and 12 co-authors. Institution: Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital. Major MEDLINE topics: Antineoplastic Agents, Carcinoma, Hepatocellular, Liver Neoplasms. Cited 4 times so far (Crossref); 29 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Aim

The aim of this retrospective multicenter study was to evaluate the differences in the timing for starting systemic therapies as the first-line treatment for hepatocellular carcinoma (HCC).

Methods

A total of 375 patients with HCC treated with sorafenib from May 2009 to March 2018 and 56 patients treated with lenvatinib from March 2018 to November 2018 at our affiliated hospitals were included in this study.

Results

The median ages of the sorafenib and lenvatinib groups were 71.0 (interquartile range [IQR] : 64.0-77.0) and 73.5 (IQR : 68.0 -80.0) years old, and 300 (80.0%) and 42 (75.0%) patients were men, respectively. The Barcelona Clinic Liver Cancer stage was early, intermediate and advanced in 39 patients (10.4%), 133 patients (35.5%) and 203 patients (54.1%) in the sorafenib group and 1 patient (1.8%), 17 patients (30.4%) and 38 patients (67.9%)in the lenvatinib group, respectively. In the analysis of intermediate HCC, patients who satisfied the criteria of TACE failure/refractoriness(P=0.017), those with ALBI grade 1 (P=0.040), and those with a serum AFP level

Subjects

MeSH terms (MEDLINE)

Antineoplastic AgentsCarcinoma, HepatocellularLiver NeoplasmsAgedHumansMaleMiddle AgedPhenylurea CompoundsQuinolinesRetrospective StudiesSorafenib

Author keywords

hepatocellular carcinomalenvatinibsorafenib

Substances

Antineoplastic AgentsPhenylurea CompoundsQuinolinesSorafeniblenvatinib

Authors and institutions

  • Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital.
  • Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine.
  • Department of Gastroenterology, National Hospital Organization Shibukawa Medical Center.
  • Department of Internal Medicine, Isesaki Municipal Hospital.
  • Department of Internal Medicine, Kiryu Kosei General Hospital.
  • Department of Gastroenterology, Maebashi Red Cross Hospital.

Cite

APA

Hatanaka, T., Kakizaki, S., Nagashima, T., Ueno, T., Namikawa, M., Tojima, H., Takizawa, D., Naganuma, A., Arai, H., Sato, K., Harimoto, N., Shirabe, K., & Uraoka, T. (2021). A change in the timing for starting systemic therapies for hepatocellular carcinoma : the comparison of sorafenib and lenvatinib as the first-line treatment. Acta Gastro Enterologica Belgica. https://doi.org/10.51821/84.1.109

Vancouver

Hatanaka T, Kakizaki S, Nagashima T, Ueno T, Namikawa M, Tojima H, et al. A change in the timing for starting systemic therapies for hepatocellular carcinoma : the comparison of sorafenib and lenvatinib as the first-line treatment. Acta Gastro Enterologica Belgica. 2021. doi:10.51821/84.1.109

BibTeX
@article{Hatanaka2021,
  author = {Hatanaka, T and Kakizaki, S and Nagashima, T and Ueno, T and Namikawa, M and Tojima, H and Takizawa, D and Naganuma, A and Arai, H and Sato, K and Harimoto, N and Shirabe, K and Uraoka, T},
  title = {A change in the timing for starting systemic therapies for hepatocellular carcinoma : the comparison of sorafenib and lenvatinib as the first-line treatment},
  journal = {Acta Gastro Enterologica Belgica},
  year = {2021},
  doi = {10.51821/84.1.109}
}
Start for free →